Naver Cloud became the first South Korean cloud service provider to develop a gene data analysis platform.
The newly-developed Nvidia Clara Parabricks on the platform of Naver Cloud, an affiliate of South Korea’s leading internet portal operator Naver Corp., is the combination of the Naver Cloud server with US graphics chip giant Nvidia Corp.’s Clara Parabricks software suite.
Clara Parabricks is a system that uses huge graphic processing units to interpret gene data.
Naver Cloud plans to launch the Genome Analysis All-in-One Integrated Platform in its marketplace in the first half of this year, in conjunction with local personal genomics business ichrogene.
Beginning with the cooperation with Nvidia and ichrogene, Naver Cloud will continue to expand its presence in the gene analysis market, according to the company’s executive director, Han Sang-young.


NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 



